Personalizing First-Line Therapy in ER-Positive, HER2-Negative Metastatic Breast Cancer

In this segment, Dr. Gregory Vidal discusses how initial treatment options are selected for patients with ER-positive, HER2-negative metastatic breast cancer and highlights the importance of individualized care. He explains that treatment decisions are not one-size-fits-all and are influenced by several clinical and personal factors. These include whether the patient has received prior endocrine therapy, the timing of recurrence, menopausal status, overall health, extent of disease, and potential side effects of treatment. Dr. Vidal also emphasizes the importance of incorporating patient preferences into decision-making, particularly when balancing treatment efficacy with quality of life. He notes that biomarker results and disease burden may further guide the selection and sequencing of therapies. This segment reinforces the principle that management of ER-positive, HER2-negative metastatic breast cancer is highly personalized, with care teams working collaboratively with patients to determine the most appropriate and sustainable treatment strategy.